WEKO3
アイテム
肝細胞癌の免疫療法に有用な新規癌胎児性抗原Glypican-3由来のHLA-A2およびA24拘束性CTLエピトープの同定
http://hdl.handle.net/2298/8122
http://hdl.handle.net/2298/81221becdacb-d76a-49e5-a394-fdb4e2e1b942
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
22-1563.pdf (4.7 MB)
|
|
| アイテムタイプ | 学位論文 / Thesis or Dissertation(1) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2014-08-13 | |||||||||||
| タイトル | ||||||||||||
| タイトル | 肝細胞癌の免疫療法に有用な新規癌胎児性抗原Glypican-3由来のHLA-A2およびA24拘束性CTLエピトープの同定 | |||||||||||
| 言語 | ja | |||||||||||
| タイトル | ||||||||||||
| タイトル | カンサイボウ ガン ノ メンエキ リョウホウ ニ ユウヨウ ナ シンキ ガン タイジセイ コウゲン Glypican-3 ユライ ノ HLA-A2 オヨビ A24 コウソクセイ CTL エピトープ ノ ドウテイ | |||||||||||
| 言語 | ja-Kana | |||||||||||
| タイトル | ||||||||||||
| タイトル | Identification of HLA-A2- or -A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy for hepatocellular carcinoma | |||||||||||
| 言語 | en | |||||||||||
| 言語 | ||||||||||||
| 言語 | jpn | |||||||||||
| キーワード | ||||||||||||
| 主題 | HLA分子, 抗腫瘍免疫, 癌胎児性抗原 GLYPICAN-3 |
|||||||||||
| 資源タイプ | ||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_46ec | |||||||||||
| 資源タイプ | thesis | |||||||||||
| 著者 |
小森, 宏之
× 小森, 宏之
|
|||||||||||
| 内容記述 | ||||||||||||
| 内容記述 | Purpose and Experimental Design: We previously reported that glypican-3 (GPC3) was overexpressed specifically in hepatocellular carcinoma (HCC) and melanoma in humans, and it was useful as a novel tumor marker for them. We also reported that the pre-immunization of BALB/c mice with dendritic cells pulsed with the H-2Kd-restricted mouse GPC3 298-306 (EYILSLEEL) peptide prevented the growth of tumor expressing mouse GPC3. Because of similarities in the binding peptide motifs between H-2Kd and HLA-A24 (A*2402), the GPC3 298-306 peptide thus seemed to be useful for the immunotherapy of HLA-A24+ patients with HCC and melanoma. In this report, we investigated whether the GPC3 298-306 peptide could induce GPC3 reactive CTLs from the peripheral blood mononuclear cells (PBMCs) of HLA-A24 (A*2402)+HCC patients. In addition, we used HLA-A2.1 (HHD) transgenic mice (Tgm) to identify the HLA-A2 (A*0201)-restricted GPC3 epitopes to expand the applications of GPC3 based immunotherapy to the HLA-A2+HCC patients. Results: We found that the GPC3 144-152 (FVGEFFTDV) peptide could induce peptide-reactive CTLs in HLA-A2.1 (HHD) Tgm without inducing autoimmunity. In 5 out of 8 HLA-A2+ GPC3+ HCC patients, the GPC3 144-152 peptide-reactive CTLs were generated from PBMCs by in vitro stimulation with the peptide and the GPC3 298-306 peptide-reactive CTLs were also generated from PBMCs in 4 of 6 HLA-A24+ GPC3+ HCC patients. The inoculation of these CTLs reduced the human HCC tumor mass implanted into NOD/SCID mice. Conclusion: Our study raises the possibility that these GPC3 reptides may therefore be applicable to cancer immunotherapy for a large number of HCC patients |
|||||||||||
| 書誌情報 |
発行年 2006-03-24 |
|||||||||||
| 著者版フラグ | ||||||||||||
| 出版タイプ | VoR | |||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||
| 日本十進分類法 | ||||||||||||
| 主題 | 377.5 | |||||||||||
| 出版者 | ||||||||||||
| 出版者 | 熊本大学 | |||||||||||
| 言語 | ja | |||||||||||
| 学位名 | ||||||||||||
| 学位名 | 博士（医学）(ja) | |||||||||||
| 学位授与機関 | ||||||||||||
| 学位授与機関名 | 熊本大学 | |||||||||||
| 学位授与年月日 | ||||||||||||
| 学位授与年月日 | 2006-03-24 | |||||||||||
| 学位授与番号 | ||||||||||||
| 学位授与番号 | 甲第1563号 | |||||||||||
| 学位番号 | ||||||||||||
| 値 | 甲博医第1563号 | |||||||||||
